In eosinophilic granulomatosis with polyangiitis (EGPA), upper and lower airway manifestations—including chronic rhinosinusitis and eosinophilic otitis media (EOM)—can persist or relapse despite high-dose anti–IL-5 therapy (1). This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.